Arbor Vita and NoNO Collaborate on Stroke Treatment
Companies seek to develop drugs targeting PDZ-protein interactions to mitigate brain damage from cerebral ischemia.!--h2>
Arbor Vita and NoNO partnered to develop and commercialize drugs for the treatment of stroke. The R&D collaboration combines Arbor Vita’s PDZ-based drug discovery platform with NoNO’s expertise in the area of neurological disorders.
“Under this collaboration, we are developing drugs targeting PDZ-protein interactions to mitigate brain damage from cerebral ischemia, which could also extend to the treatment of neurotrauma, pain, Alzheimer’s, and other diseases,” states Peter Lu, M.D., founder, president, and CEO of Arbor Vita.